NCT04925544进行中（未招募）2 期
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- Response rate
研究概览
简要总结
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available
详细描述
Primary Objective: To characterize the anti tumor effect of VK 2019 in subjects with EBV related cancer.
Secondary Objective: 1. To characterize the safety profile, survival, PK and PD in the studied subject populations 2. To explore clinical activity and safety on subjects with post transplant lymphoproliferative disorder (PTLD) and EBV related lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1 Informed consent obtained prior to any protocol mandated study specific procedures in accordance with institutional policies.
- •2 Either loco regionally recurrent or metastatic EBV positive RECIST evaluable nasopharyngeal carcinoma not amenable to curative treatment with no accepted effective standard of care therapeutic option.
- •Addendum for phase 2 exploratory cohorts: subjects with PTLD or EBV lymphoma not amenable to curative treatment with no accepted effective standard of care therapeutic option.
- •3 Not eligible for other approved or standard therapies
- •4.Prior palliative radiation must have been completed at least 2 weeks prior to study Cycle 1 Day 0
- •5.Prior anti cancer systemic treatment must have been completed greater than 4 weeks prior to the first dose of VK 2019 or subjects must have recovered from all acute prior treatment related AEs
- •6.Toxicities related to prior anti cancer therapy must have returned to Grade 1 or less. Peripheral neuropathy must be Grade 2 or less. Chronic but stable toxicities Grade > 1 (eg, dysphasia, G tube dependence, etc.) are permissible.
- •7.Age ≥ 18
- •8.Absolute neutrophil count > 1500/µL (stable off any growth factor for at least 1 week of study drug administration)
- •9.Hemoglobin > 9g/dL (transfusion to achieve this level is permitted)
- •10.Platelet count > 75 x 103/ µL (transfusion to achieve this level is NOT permitted)
- •11.Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) .Total serum bilirubin ≤ 1.5 x ULN
- •12.Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min as calculated per Cockcroft Gault equation
- •13.Urinary protein < 2+ by dipstick. If dipstick ≥ 2+, then a 24 hour urine collection can be done and the subject may enter only if urinary protein is < 1 g/24 hour
- •14.Sexually active subjects must agree to utilize birth control method during treatment and for 18 weeks after the last dose of VK
- •15.Eastern Cooperative Oncology Group (ECOG) performance status 2 or less.
- •16.Ability to understand and the willingness to personally sign the written IRB approved informed consent document.
排除标准
- •1.Prior therapy restrictions.
- •2.Concurrent treatment with systemic cancer directed therapy including complementary, alternative, herbal or nutritional supplement based treatments whose purpose is for anti cancer effect
- •3.Severe or active symptomatic cardiopulmonary diseases, including unstable angina, congestive heart failure, or peripheral vascular disease within 12 months prior to study drug administration; and/or chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 4 weeks prior to study drug administration. Subjects with effectively treated conditions (eg, stenting for coronary artery disease) are eligible if stable for at least 4 weeks prior to study drug administration
- •4.Metastatic disease with active central nervous system (CNS) involvement, defined as parenchymal brain involvement. Subjects with cranial nerve or base of skull involvement without the above are eligible. Subjects with CNS metastases that are stable on imaging at least 1 month following focal treatment with radiation are eligible
- •5.Known history of human immunodeficiency virus (HIV) unless the HIV positive subjects has:
- •A stable regimen of highly active anti retroviral therapy (HAART)
- •No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
- •A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR based test
- •6.Serious uncontrolled medical disorder or active infection which would, in the opinion of the Investigator, impair the ability of the subject to receive protocol therapy or whose control may be jeopardized by the complications of this therapy
- •7.NPC subjects: Have received a prior organ allograft or allogeneic bone marrow transplant.
- •8.Current non prescription drug or alcohol dependence
- •9.For all female subjects: pregnancy or breastfeeding
- •10.All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment
- •11.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the subject inappropriate for entry into the study
- •12.Corrected QT by Fridericia's formula (QTcF) of > 470 ms average (mean) on triplicate ECG performed during screening
研究组 & 干预措施
VK-2019_arm
Experimental
Dose escalation and expansion up to 31 additional patients at a maximum of 1800 mg twice daily. Cycles will be defined as 28 days of treatment, subjects will receive VK 2019 until progression or dose limiting toxicity, for up to 12 cycles.
干预措施: VK-2019 (Drug)
结局指标
主要结局
Response rate
时间窗: 12 months
Response rate to VK 2019 in EBV related NPC subjects will be assessed using RECIST v 1.1 criteria. Response Evaluable Subjects: All treated subjects with measurable disease at baseline and one of the following: 1) at least one post dose tumor assessment, 2) discontinuation prior to the first efficacy assessment due to clinical disease progression or toxicity or 3) death either on treatment or within 28 days of last VK 2019 dose.
次要结局
- Peak Plasma Concentration (Cmax)(Day 56 (ie, Day 0 Cycle 3 after 2, (each cycle is 28 days))
- Safety profile(12 months)
- Area under the plasma concentration versus time curve (AUC)(Day 56 (ie, Day 0 Cycle 3 after 2, (each cycle is 28 days))
- Overall survival(24 months)
- Time to maximum plasma concentration (Tmax),(Day 56 (ie, Day 0 Cycle 3 after 2, (each cycle is 28 days))
- Pharmacodynamic EBV DNA(Day 56 (ie, Day 0 Cycle 3 after,2 (each cycle is 28-day))
- Progression free survival(24 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT02761291Chang Gung Memorial Hospital18
已完成
2 期
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal CancerNasopharyngeal Nonkeratinizing CarcinomaRecurrent Nasopharynx CarcinomaStage III Nasopharyngeal Carcinoma AJCC v7Stage IV Nasopharyngeal Carcinoma AJCC v7Stage IVA Nasopharyngeal Carcinoma AJCC v7Stage IVB Nasopharyngeal Carcinoma AJCC v7Stage IVC Nasopharyngeal Carcinoma AJCC v7NCT02339558National Cancer Institute (NCI)45
终止
3 期
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNANasopharyngeal CarcinomaNCT02363400National Health Research Institutes, Taiwan10
进行中（未招募）
2 期
Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaLocally Advanced Nasopharyngeal CarcinomaNCT04910347Yonsei University57
进行中（未招募）
1 期
DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDYadvanced or metastatic Nose Pharynx CancerMedDRA version: 21.0Level: LLTClassification code 10028793Term: Nasopharyngeal carcinomaSystem Organ Class: 100000004864EUCTR2017-005017-31-ITG.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST47